Adjuvant medications that improve survival after locoregional therapy Journal Article

   


Authors: Boas, F. E.; Ziv, E.; Yarmohammadi, H.; Brown, K. T.; Erinjeri, J. P.; Sofocleous, C. T.; Harding, J. J.; Solomon, S. B.
Article Title: Adjuvant medications that improve survival after locoregional therapy
Abstract: Purpose To determine if outpatient medications taken at the time of liver tumor embolization or ablation affect survival. Materials and Methods A retrospective review was done of 2,032 liver tumor embolization, radioembolization, and ablation procedures performed in 1,092 patients from June 2009 to April 2016. Pathology, hepatocellular carcinoma (HCC) stage (American Joint Committee on Cancer), neuroendocrine tumor (NET) grade, initial locoregional therapy, overall survival after initial locoregional therapy, Child-Pugh score, Eastern Cooperative Oncology Group performance status, Charlson Comorbidity Index, and outpatient medications taken at the time of locoregional therapy were analyzed for each patient. Kaplan-Meier survival curves were calculated for patients taking 29 medications or medication classes (including prescription and nonprescription medications) for reasons unrelated to their primary cancer diagnosis. Kaplan-Meier curves were compared using the log-rank test. Results For patients with HCC initially treated with embolization (n = 304 patients), the following medications were associated with improved survival when taken at the time of embolization: beta-blockers (P =.0007), aspirin (P =.0008) and other nonsteroidal antiinflammatory drugs (P =.009), proton pump inhibitors (P =.004), and antivirals for hepatitis B or C (P =.01). For colorectal liver metastases initially treated with ablation (n = 172 patients), beta-blockers were associated with improved survival when taken at the time of ablation (P =.02). Conclusions Aspirin and beta-blockers are associated with significantly improved survival when taken at the time of embolization for HCC. Aspirin was not associated with survival differences after locoregional therapy for NET or colorectal liver metastases, suggesting an HCC-specific effect. © 2017 SIR
Journal Title: Journal of Vascular and Interventional Radiology
Volume: 28
Issue: 7
ISSN: 1051-0443
Publisher: Elsevier Science, Inc.  
Date Published: 2017-07-01
Start Page: 971
End Page: 977.e4
Language: English
DOI: 10.1016/j.jvir.2017.04.016
PROVIDER: scopus
PMCID: PMC5502720
PUBMED: 28527884
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020098711&doi=10.1016%2fj.jvir.2017.04.016&partnerID=40&md5=34b6bbc4b6508c8df5b685ea554fef6b
Notes: Article -- Export Date: 1 August 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. James Joseph Harding
    250 Harding
  2. Karen T Brown
    178 Brown
  3. Stephen Solomon
    424 Solomon
  4. Joseph Patrick Erinjeri
    203 Erinjeri
  5. Constantinos T Sofocleous
    245 Sofocleous
  6. Hooman Yarmohammadi
    131 Yarmohammadi
  7. Franz Edward Boas
    77 Boas
  8. Etay Ziv
    112 Ziv
Related MSK Work